SEC Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Vallon Pharmaceuticals, Inc. on February 28, 2022, reporting events occurring on February 23, 2022. The provided request identifies the company as GRI Bio, Inc.; however, the filing names Vallon Pharmaceuticals, Inc. as the registrant. The company’s common stock traded under the symbol VLON on the Nasdaq Capital Market.
Board and Governance Changes
- The Board increased its size from five to six directors.
- Meenu Karson was appointed to the Board, serving until her successor is elected and qualified or until her earlier death, resignation, or removal.
- The Board determined that Ms. Karson qualifies as an independent director under applicable Nasdaq and Securities Exchange Act requirements.
- Ofir Levi resigned from the Audit Committee and from the Nominating and Corporate Governance Committee, including as its chair.
- Ms. Karson was appointed to the Audit Committee and as a member and chair of the Nominating and Corporate Governance Committee.
- Dr. Levi remains a director and continues to serve as chair of the Board.
Financial Metrics and Liquidity
The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other financial operating metrics. It is a governance-related Form 8-K rather than a financial results filing.
Compensation, Outlook, and Other Matters
- Ms. Karson will receive compensation under the company’s existing director compensation policy.
- She entered into the company’s standard Directors’ and Officers’ Indemnity Agreement.
- A February 28, 2022 press release announcing her appointment was filed as Exhibit 99.1.
- No financial guidance, business outlook, material contingency, or unusual financial item is disclosed in the provided filing text.
Important Facts to Verify
- Confirm whether the filing relates to Vallon Pharmaceuticals, Inc. or GRI Bio, Inc., because the request metadata and filing name do not match.
- Review Exhibit 99.1 for additional information about Ms. Karson and her appointment.
- Verify the applicable director compensation policy and indemnification terms.
- Assess whether the committee changes affect audit oversight, corporate governance, or future filings.